Attention deficit hyperactivity disorder
GPTKB entity
Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:neurological_disorder
|
| gptkbp:abbreviation |
ADHD
|
| gptkbp:affects |
adults
children |
| gptkbp:associatedWith |
academic difficulties
executive function deficits occupational difficulties social difficulties |
| gptkbp:characterizedBy |
hyperactivity
impulsivity inattention |
| gptkbp:commonMedication |
gptkb:clonidine
gptkb:atomoxetine gptkb:amphetamine gptkb:methylphenidate guanfacine |
| gptkbp:comorbidity |
gptkb:depression
gptkb:conduct_disorder gptkb:oppositional_defiant_disorder learning disabilities anxiety disorders |
| gptkbp:controversy |
gptkb:diagnosis
overdiagnosis medication use in children |
| gptkbp:diagnosedBy |
clinical assessment
behavioral observation |
| gptkbp:DSM-5_code |
314.00
|
| gptkbp:fieldOfStudy |
neurology
pediatrics psychiatry psychology |
| gptkbp:firstDescribed |
1902
|
| gptkbp:ICD-10_code |
gptkb:F90
|
| gptkbp:prevalence |
2.5% of adults worldwide
5% of children worldwide |
| gptkbp:riskFactor |
genetics
premature birth prenatal exposure to tobacco prenatal exposure to alcohol |
| gptkbp:subspecies |
combined presentation
predominantly hyperactive-impulsive presentation predominantly inattentive presentation |
| gptkbp:symptom |
forgetfulness
disorganization difficulty sustaining attention difficulty waiting turn excessive talking fidgeting interrupting others |
| gptkbp:treatment |
gptkb:psychotherapy
behavioral therapy psychoeducation stimulant medication |
| gptkbp:bfsParent |
gptkb:Specific_developmental_disorders_of_speech_and_language
gptkb:Dopaminergic_Agents gptkb:Dopamine_(in_brain) gptkb:Cognitive_Assessment |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Attention deficit hyperactivity disorder
|